Ge Wu

Dr. Ge Wu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Advanced Science
Verified
Journal Article
Open access
PDF file
ZRZhigang Ren
Zhigang Ren
YFYajuan Fan
Yajuan Fan
ALAng Li
Ang Li
QSQuanquan Shen
Quanquan Shen
JWJian Wu
Jian Wu
LLLanjuan Li
Lanjuan Li
Gut microbiota make up the largest microecosystem in the human body and are closely related to chronic metabolic diseases. Herein, 520 fecal samples are collected from different regions of China, the gut microbiome in chronic kidney disease (CKD) is characterized, and CKD classifiers based on microbial markers are constructed. Compared with healthy controls (HC, n = 210), gut microbial diversity is significantly decreased in CKD (n = 110), and the microbial community is remarkably distinguished from HC. Genera Klebsiella and Enterobacteriaceae are enriched, while Blautia and Roseburia are reduced in CKD. Fifty predicted microbial functions including tryptophan and phenylalanine metabolisms increase, while 36 functions including arginine and proline metabolisms decrease in CKD. Notably, five optimal microbial markers are identified using the random forest model. The area under the curve (AUC) reaches 0.9887 in the discovery cohort and 0.9512 in the validation cohort (49 CKD vs 63 HC). Importantly, the AUC reaches 0.8986 in the extra diagnosis cohort from Hangzhou. Moreover, Thalassospira and Akkermansia are increased with CKD progression. Thirteen operational taxonomy units are correlated with six clinical indicators of CKD. In conclusion, this study comprehensively characterizes gut microbiome in non‐dialysis CKD and demonstrates the potential of microbial markers as non‐invasive diagnostic tools for CKD in different regions of China.

10 May 2022 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
SGShiyuan Guo
Shiyuan Guo
GWGe Wu
Ge Wu
WLWenli Liu
Wenli Liu
YFYajuan Fan
Yajuan Fan
WSWengang Song
Wengang Song
ZLZhangsuo Liu
Zhangsuo Liu
Background: Morbidity of chronic kidney disease (CKD) is increased, with many complications and high mortality rates. The characteristics of oral microbiome in CKD patients have not been reported. This study aims to analyze the oral microbiome, and to demonstrate the potential of microbiome as noninvasive biomarkers for CKD patients. Methods: The study collected 253 oral samples from different regions of China (Central China and East China) prospectively and finally 235 samples completed Miseq sequencing, including 103 samples from CKD patients and 132 healthy controls (HCs). Results: Compared with HCs (n=88), the oral microbial diversity in CKD patients (n=44) was increased. Fourteen genera including Streptococcus, Actinomyces and Leptotrichia were enriched, while six genera including Prevotella and Haemophilus were decreased in CKD patients. Moreover, 49 predicted microbial gene functions including arginine metabolism and tryptophan metabolism increased, while 55 functions including Ribosome and DNA repair recombination proteins decreased. Furthermore, correlation analysis demonstrated that 38 operational taxonomic units (OTUs) were closely related to 5 clinical indicators of CKD. Notably, 7 optimal biomarkers were identified using random forest model, and the classifier model respectively reached an area under the curve (AUC) of 0.9917 and 0.8026 in the discovery and validation phase, achieving a cross-region validation. Conclusions: We first illustrated the characteristics of the oral microbiome of patients with CKD, identified the potential of oral microbial makers as noninvasive tools for the diagnosis of CKD and achieved cross-region validation.

8 October 2024 in Renal Failure
Verified
Journal Article
Open access
XGXi Gu
Xi Gu
YDYindi Dong
Yindi Dong
XWXuemei Wang
Xuemei Wang
ZRZhigang Ren
Zhigang Ren
GLGuanhua Li
Guanhua Li
ZLZhangsuo Liu
Zhangsuo Liu
This study aimed to identify biomarkers for chronic kidney disease (CKD) by studying serum metabolomics. Serum samples were collected from 194 non-dialysis CKD patients and 317 healthy controls (HC). Using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS), untargeted metabolomics analysis was conducted. A random forest model was developed and validated in separate sets of HC and CKD patients. The serum metabolomic profiles of patients with chronic kidney disease (CKD) exhibited significant differences compared to healthy controls (HC). A total of 314 metabolites were identified as significantly different, with 179 being upregulated and 135 being downregulated in CKD patients. KEGG enrichment analysis revealed several key pathways, including arginine biosynthesis, phenylalanine metabolism, linoleic acid metabolism, and purine metabolism. The diagnostic efficacy of the classifier was high, with an area under the curve of 1 in the training and validation sets and 0.9435 in the cross-validation set. This study provides comprehensive insights into serum metabolism in non-dialysis CKD patients, highlighting the potential involvement of abnormal biological metabolism in CKD pathogenesis. Exploring metabolites may offer new possibilities for the management of CKD.

30 September 2026 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Open access
PDF file
MYMiaoyu Yin
Miaoyu Yin
MLMengdi Li
Mengdi Li
YZYan Zhang
Yan Zhang
BWBingxiao Wang
Bingxiao Wang
GLGuanhua Li
Guanhua Li
GWGe Wu
Ge Wu
Gut microbiota has been implicated in chronic kidney disease (CKD) progression. Probiotics such as Lactobacillus may alleviate renal injury through metabolic modulation, whereas tryptophan metabolism may have divergent effects in CKD. However, whether Lactobacillus and tryptophan supplementation are associated with distinct or overlapping metabolic profiles in CKD remains unclear. This study aimed to evaluate the effects of Lactobacillus and tryptophan supplementation and characterize the associated serum and fecal metabolomic alterations in an adenine-induced CKD mouse model. Six-week-old male mice were fed adenine for 3 weeks to induce CKD, followed by 8 weeks of treatment: saline for control (NC, CKD), Lactobacillus (2 × 10 7 CFU; CKD + Lac), or Tryptophan (4 mmol/kg; CKD + Try). Renal function markers (SCr, BUN, CysC), inflammatory markers (CRP, PCT), and histopathology were assessed at experimental endpoint (week 12). Serum and fecal metabolomics were analyzed using UPLC-HDMS, followed by PCA, OPLS-DA and KEGG pathway enrichment analyses. Adenine induced significant renal injury, as indicated by elevated SCr, BUN, CysC, CRP, and PCT levels, together with marked interstitial fibrosis and tubular epithelial degeneration. These alterations were partially attenuated by either Lactobacillus or tryptophan supplementation. In CKD + Lac mice, 250 serum and 332 fecal metabolites were altered across 5 pathways, including tyrosine, β-alanine, and riboflavin metabolism, prolactin signaling, and ABC transporters. In CKD + Try mice, 310 serum and 381 fecal metabolites were changed, involving tyrosine, biotin, linoleic acid, and amino acid metabolism, prolactin signaling, lipolysis, and arginine biosynthesis. Both Lactobacillus and tryptophan supplementation partially improved renal function and attenuated renal injury in adenine-induced CKD mice and were associated with altered serum and fecal metabolite profiles involving tyrosine, arginine, and related metabolic pathways. Not applicable.